Welcome to our dedicated page for Health In Tech SEC filings (Ticker: HIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health In Tech, Inc. filings document material-event disclosures for a Nevada operating company with Class A common stock listed on the Nasdaq Capital Market under HIT. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD materials, investor presentations and conference-call transcripts.
The filing record also addresses capital-structure matters, including a private investment in public equity financing, and governance disclosures involving executive officer departures, compensatory arrangements and related consulting agreements. The company identifies as an emerging growth company in its Exchange Act reports.
Health In Tech, Inc. is soliciting votes for its annual meeting and has mailed a Proxy Statement and Annual Report to holders of record as of August 6, 2025. The filing outlines meeting logistics, voting procedures (including a telephonic proxy deadline of 11:59 p.m. ET on October 2, 2025), broker voting treatment for "routine" items, and deadlines for stockholder proposals and director nomination notices for the 2026 meeting (May 13, 2026 for proposals; August 4, 2026 for contested-nomination notices under Rule 14a-19).
The statement identifies the company's executive officers and board members, describes committee charters and responsibilities (audit, compensation, nominating/governance), discloses a related-party services amounting to $940,915 through May 31, 2023, and notes corporate actions including a retroactive stock split effected June 4, 2024. Director compensation includes an $80,000 restricted stock award for non-employee directors vesting after one year. The Audit Committee reports pre-approval of Malone Bailey's 2024 services.
Health In Tech, Inc. (HIT) reporting person LinLin Qian, who serves as Chief Financial Officer, Director and a reported 10% owner, received a grant of 27,000 restricted shares of Class A Common Stock on 08/15/2025. The restricted shares were issued under the Health in Tech Equity Incentive Plan and vest based on operational milestones: 50% vest monthly over 12 months after the first specified program is launched and operational, and the remaining 50% vest monthly over 12 months after the second specified program is launched and operational. Following the transaction the reporting person beneficially owns 8,048,555 shares (which the filing states include 55,193 restricted shares and 7,993,362 Class A shares), while the filing excludes certain Class B shares and options.
Tim Johnson, the Chief Executive Officer, Director and 10% owner of Health In Tech, Inc. (HIT), was granted 34,000 restricted shares of Class A Common Stock on 08/15/2025. The shares were granted at $0 and are subject to performance-based vesting tied to the successful launch and full operation of two specified company programs: 50% vest monthly over 12 months after the first program is launched and operational, and the remaining 50% vest monthly over 12 months after the second program is launched and operational. After this grant the reporting person beneficially owns 22,469,741 shares, which the filing clarifies includes 62,193 restricted shares and 22,407,548 Class A shares and expressly excludes 9,000,000 Class B shares and 734,707 options to purchase Class A shares.
Health In Tech, Inc. (HIT) reporting person Imran Yousuf, Chief Technology Officer and Director, received a grant of 7,000 restricted Class A common shares on 08/15/2025. The restricted shares are subject to vesting tied to two separate product launches: 50% vests monthly over 12 months after the first specified program is successfully launched and operational, and the remaining 50% vests monthly over 12 months after the second specified program is successfully launched and operational. Following the grant the reporting person beneficially owns 107,000 shares (comprised of 100,000 shares and 7,000 restricted shares). The filing excludes 100,000 options to purchase Class A common stock.
Health In Tech insider Jonathan Del Lockett reported a grant of 7,000 restricted shares of Class A common stock on 08/15/2025. The restricted shares were granted under the Health in Tech Equity Incentive Plan and carry vesting conditions tied to the successful launch and full operation of two specified company programs: 50% of the restricted shares vest monthly over 12 months after the first program is launched, and the remaining 50% vest monthly over 12 months after the second program is launched. Following the reported transaction, Mr. Lockett beneficially owns 93,539 shares (including 22,105 restricted shares and 71,434 unrestricted Class A shares); the filing notes he also holds 165,085 options to purchase Class A common stock that are excluded from the ownership total.
Health In Tech, Inc. reported that its Compensation Committee approved new restricted stock awards for three senior executives tied to the development of two new programs, referred to as Program 1 and Program 2. Chief Executive Officer Tim Johnson was granted 17,000 shares for each program, Chief Financial Officer Linlin (Julia) Qian was granted 10,000 shares for Program 1 and 17,000 shares for Program 2, and Chief Technology Officer (Mo) Imran Yousuf was granted 3,500 shares for each program.
Half of each executive’s grant will vest in equal monthly installments over twelve months starting when the first of the two programs is successfully launched and fully operational in the marketplace. The remaining half will vest in equal monthly installments over twelve months starting when the other program is successfully launched and fully operational. These awards were made under the company’s Equity Incentive Plan and follow previously approved restricted stock award agreements.
Health In Tech, Inc. reported accelerating revenue and margin expansion for the six months ended June 30, 2025. Total revenues rose to $17.33 million from $10.13 million a year earlier, driven by higher fees and underwriting modeling services, producing gross profit of $11.67 million and net income of $1.13 million, up from $438,543. Cash and cash equivalents increased modestly to $8.14 million, supported in part by net IPO proceeds of $8.21 million received previously.
The balance sheet shows growth in non-current and other receivables to $3.85 million, reflecting purchases of deferred administrative surplus; accounts payable rose to $4.33 million. The company recognized a refund liability of $955,743 tied to a variable reconciliation clause with a carrier and recorded stock-based compensation expense of $1.20 million during the period. Significant customer and vendor concentrations and collection uncertainty on purchased receivables are material risks disclosed in the filing.